Abbott LaboratoriesABTNYSE
Loading
ABT Revenue Growth (YoY Quarterly)•+4.42%
Stock Alarm Pro
Growth Metrics
Latest: Q4 2025vs Q3 2025
Revenue GrowthGross Profit GrowthEBITDA GrowthOperating Income GrowthNet Income GrowthEPS GrowthEPS Diluted GrowthWeighted Average Shares GrowthWeighted Average Shares Diluted GrowthDividends per Share Growth
+4.42%
-2.5pp
+16.77%
-0.0pp
-5.59%
-12.0pp
+13.12%
-0.0pp
-80.76%
-80.6pp
-80.86%
-79.8pp
-80.65%
-80.6pp
+0.88%
+0.0pp
+0.06%
+0.0pp
+0.00%
+0.0pp
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +7.16% | +3.95% | +7.37% | +6.90% | +4.42% |
| Gross Profit Growth | +6.47% | +8.40% | +18.53% | +16.81% | +16.77% |
| EBITDA Growth | +5.14% | +13.15% | +18.14% | +6.36% | -5.59% |
| Operating Income Growth | +6.76% | +21.88% | +21.71% | +13.15% | +13.12% |
| Net Income Growth | +478.98% | +8.16% | +36.64% | -0.12% | -80.76% |
| EPS Growth | +479.35% | +6.81% | +36.00% | -1.05% | -80.86% |
| EPS Diluted Growth | +479.12% | +8.34% | +36.49% | +0.00% | -80.65% |
| Weighted Average Shares Growth | -0.14% | +0.76% | +0.37% | +0.84% | +0.88% |
| Weighted Average Shares Diluted Growth | -0.11% | -0.16% | +0.00% | +0.06% | +0.06% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -5.60% | +38.24% | +4.44% | +3.03% | +15.59% |
| Free Cash Flow Growth | -5.91% | +48.80% | +8.27% | +6.61% | +22.25% |
| Receivables Growth | +5.48% | +10.93% | +16.31% | +15.42% | +14.50% |
| Inventory Growth | -5.72% | -2.75% | +2.05% | -1.54% | +4.75% |
| Asset Growth | +11.20% | +12.39% | +15.04% | +13.21% | +6.51% |
| Book Value per Share Growth | +23.64% | +24.82% | +28.13% | +26.97% | +8.41% |
| Debt Growth | -3.77% | -9.21% | -8.93% | -13.61% | -1.36% |
| R&D Expense Growth | +5.51% | +2.93% | +5.02% | +10.10% | +0.96% |
| SG&A Expenses Growth | +6.51% | +3.35% | +5.85% | +7.18% | +8.65% |
1 / 4